APA (7th ed.) Citation

Chiam, P. J., Ho, V. W., Hickley, N. M., & Kotamarthi, V. (2016). 6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration： a 2-year outcome. International journal of ophthalmology, 9(4), 551-555. https://doi.org/10.18240/ijo.2016.04.12

Chicago Style (17th ed.) Citation

Chiam, Patrick J., Vivian W. Ho, Nicholas M. Hickley, and Venkat Kotamarthi. "6-weekly Bevacizumab Versus 4-weekly Ranibizumab for Neovascular Age-related Macular Degeneration： a 2-year Outcome." International Journal of Ophthalmology 9, no. 4 (2016): 551-555. https://doi.org/10.18240/ijo.2016.04.12.

MLA (9th ed.) Citation

Chiam, Patrick J., et al. "6-weekly Bevacizumab Versus 4-weekly Ranibizumab for Neovascular Age-related Macular Degeneration： a 2-year Outcome." International Journal of Ophthalmology, vol. 9, no. 4, 2016, pp. 551-555, https://doi.org/10.18240/ijo.2016.04.12.